Oncology Stocks Surge as Breakthrough Therapies Transform Cancer Treatment
Cancer is the second leading cause of death worldwide, and oncology is one of the biggest sectors in the life science space. Companies like Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), and Sanofi (NASDAQ:SNY) are working to develop best-in-class therapeutics for various cancers.
Amgen's lung cancer therapy Imdelltra posted 115% year-over-year sales growth in the second quarter, while Gilead's breast cancer treatment Trodelvy saw a 26% increase in sales. Sanofi's Sarclisa Escena received its first subcutaneous approvals in the US, EU, and Japan.
Regeneron Pharmaceuticals (NASDAQ:REGN) is developing medicines for cancer, pain, and other diseases. Its two approved cancer drugs, Libtayo and Lyonzivic, are gaining traction. Revolution Medicines (NASDAQ:RVMD) is focused on developing targeted therapies for RAS-addicted cancers.
These companies are making significant advancements in oncology, with innovative new therapies being developed to treat various types of cancer. Investors who want exposure to the sector should consider looking at biotech and pharma companies with a focus on cancer drugs, vaccines, and therapies.